Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-07-2011 | Review Article

Molecular imaging in patients with mood disorders: a review of PET findings

Authors: Qiaozhen Chen, Weibo Liu, Huichun Li, Hong Zhang, Mei Tian

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 7/2011

Abstract

Mood disorders are chronic, recurrent psychiatric disorders with high morbidity rates that cause severe disability. Researchers have used molecular imaging extensively in studies of mood disorders. In this article, we concisely and selectively review the major findings of positron emission tomography studies of patients with mood disorders. Specifically, we describe findings from cerebral blood flow, cerebral glucose/oxygen metabolism, and radioligand studies in both cross-sectional and longitudinal investigations. Patients with mood disorders have mood-correlated regional metabolism changes and molecular abnormalities in several neurotransmitter systems. Although the findings of these studies are not completely consistent and confounding factors, including drug effects and specific methodology, should be strictly controlled, these results reveal the pathophysiology of mood disorders and aid the development of novel treatment approaches for mood disorders. Future positron emission tomography research will benefit greatly from the development of better radioligands to simultaneously identify multiple neurotransmitter systems in the specific brain region and the integration of more detecting methods in specifying the neurobiological predictors of treatment response in patients with mood disorders. Understanding the molecular mechanisms in underlying mood disorders will result in aetiological diagnosis and individualization of treatment of these disorders.

Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62(6):593–602.PubMedCrossRef

Phillips MR, Zhang J, Shi Q, Song Z, Ding Z, Pang S, et al. Prevalence, treatment, and associated disability of mental disorders in four provinces in China during 2001–05: an epidemiological survey. Lancet. 2009;373(9680):2041–53.PubMedCrossRef

World Health Organization. The global burden of disease: 2004 update. 1st ed. World Health Organization; 2008.

Zipursky RB, Meyer JH, Verhoeff NP. PET and SPECT imaging in psychiatric disorders. Can J Psychiatry. 2007;52(3):146–57.PubMed

Bench CJ, Friston KJ, Brown RG, Frackowiak RS, Dolan RJ. Regional cerebral blood flow in depression measured by positron emission tomography: the relationship with clinical dimensions. Psychol Med. 1993;23(3):579–90.PubMedCrossRef

Baxter Jr LR, Schwartz JM, Phelps ME, Mazziotta JC, Guze BH, Selin CE, et al. Reduction of prefrontal cortex glucose metabolism common to three types of depression. Arch Gen Psychiatry. 1989;46(3):243–50.PubMed

Buchsbaum MS, Wu J, Siegel BV, Hackett E, Trenary M, Abel L, et al. Effect of sertraline on regional metabolic rate in patients with affective disorder. Biol Psychiatry. 1997;41(1):15–22.PubMedCrossRef

Kennedy SH, Evans KR, Kruger S, Mayberg HS, Meyer JH, McCann S, et al. Changes in regional brain glucose metabolism measured with positron emission tomography after paroxetine treatment of major depression. Am J Psychiatry. 2001;158(6):899–905.PubMedCrossRef

Kimbrell TA, Ketter TA, George MS, Little JT, Benson BE, Willis MW, et al. Regional cerebral glucose utilization in patients with a range of severities of unipolar depression. Biol Psychiatry. 2002;51(3):237–52.PubMedCrossRef

10.

Hosokawa T, Momose T, Kasai K. Brain glucose metabolism difference between bipolar and unipolar mood disorders in depressed and euthymic states. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33(2):243–50.PubMedCrossRef

11.

Baxter Jr LR. Phelps ME, Mazziotta JC, Schwartz JM, Gerner RH, Selin CE, et al. Cerebral metabolic rates for glucose in mood disorders. Studies with positron emission tomography and fluorodeoxyglucose F18. Arch Gen Psychiatry. 1985;42(5):441–7.PubMed

12.

Ketter TA, Kimbrell TA, George MS, Dunn RT, Speer AM, Benson BE, et al. Effects of mood and subtype on cerebral glucose metabolism in treatment-resistant bipolar disorder. Biol Psychiatry. 2001;49(2):97–109.PubMedCrossRef

13.

Brooks III JO, Wang PW, Bonner JC, Rosen AC, Hoblyn JC, Hill SJ, et al. Decreased prefrontal, anterior cingulate, insula, and ventral striatal metabolism in medication-free depressed outpatients with bipolar disorder. J Psychiatr Res. 2009;43(3):181–8.PubMedCrossRef

14.

Drevets WC, Price JL, Simpson Jr JR, Todd RD, Reich T, Vannier M, et al. Subgenual prefrontal cortex abnormalities in mood disorders. Nature. 1997;386(6627):824–7.PubMedCrossRef

15.

Brooks III JO, Hoblyn JC, Ketter TA. Metabolic evidence of corticolimbic dysregulation in bipolar mania. Psychiatry Res. 2010;181(2):136–40.PubMedCrossRef

16.

Drevets WC, Price JL, Bardgett ME, Reich T, Todd RD, Raichle ME. Glucose metabolism in the amygdala in depression: relationship to diagnostic subtype and plasma cortisol levels. Pharmacol Biochem Behav. 2002;71(3):431–47.PubMedCrossRef

17.

Mah L, Zarate Jr CA, Singh J, Duan YF, Luckenbaugh DA, Manji HK, et al. Regional cerebral glucose metabolic abnormalities in bipolar II depression. Biol Psychiatry. 2007;61(6):765–75.PubMedCrossRef

18.

Drevets WC, Bogers W, Raichle ME. Functional anatomical correlates of antidepressant drug treatment assessed using PET measures of regional glucose metabolism. Eur Neuropsychopharmacol. 2002;12(6):527–44.PubMedCrossRef

19.

Blumberg HP, Stern E, Martinez D, Ricketts S, de Asis J, White T, et al. Increased anterior cingulate and caudate activity in bipolar mania. Biol Psychiatry. 2000;48(11):1045–52.PubMedCrossRef

20.

Ressler KJ, Mayberg HS. Targeting abnormal neural circuits in mood and anxiety disorders: from the laboratory to the clinic. Nat Neurosci. 2007;10(9):1116–24.PubMedCrossRef

21.

aan het Rot M, Mathew SJ, Charney DS. Neurobiological mechanisms in major depressive disorder. CMAJ. 2009;180(3):305–13.

22.

Kennedy SH, Konarski JZ, Segal ZV, Lau MA, Bieling PJ, McIntyre RS, et al. Differences in brain glucose metabolism between responders to CBT and venlafaxine in a 16-week randomized controlled trial. Am J Psychiatry. 2007;164(5):778–88.PubMedCrossRef

23.

Milak MS, Parsey RV, Lee L, Oquendo MA, Olvet DM, Eipper F, et al. Pretreatment regional brain glucose uptake in the midbrain on PET may predict remission from a major depressive episode after three months of treatment. Psychiatry Res. 2009;173(1):63–70.PubMedCrossRef

24.

Schildkraut JJ. The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry. 1965;122(5):509–22.PubMed

25.

Drevets WC, Frank E, Price JC, Kupfer DJ, Holt D, Greer PJ, et al. PET imaging of serotonin 1A receptor binding in depression. Biol Psychiatry. 1999;46(10):1375–87.PubMedCrossRef

26.

Sargent PA, Kjaer KH, Bench CJ, Rabiner EA, Messa C, Meyer J, et al. Brain serotonin1A receptor binding measured by positron emission tomography with [11C]WAY-100635: effects of depression and antidepressant treatment. Arch Gen Psychiatry. 2000;57(2):174–80.PubMedCrossRef

27.

Hirvonen J, Karlsson H, Kajander J, Lepola A, Markkula J, Rasi-Hakala H, et al. Decreased brain serotonin 5-HT1A receptor availability in medication-naive patients with major depressive disorder: an in-vivo imaging study using PET and [carbonyl-11C]WAY-100635. Int J Neuropsychopharmacol. 2008;11(4):465–76.PubMedCrossRef

28.

Drevets WC, Thase ME, Moses-Kolko EL, Price J, Frank E, Kupfer DJ, et al. Serotonin-1A receptor imaging in recurrent depression: replication and literature review. Nucl Med Biol. 2007;34(7):865–77.PubMedCrossRef

29.

Meltzer CC, Price JC, Mathis CA, Butters MA, Ziolko SK, Moses-Kolko E, et al. Serotonin 1A receptor binding and treatment response in late-life depression. Neuropsychopharmacology. 2004;29(12):2258–65.PubMedCrossRef

30.

Bhagwagar Z, Rabiner EA, Sargent PA, Grasby PM, Cowen PJ. Persistent reduction in brain serotonin1A receptor binding in recovered depressed men measured by positron emission tomography with [11C]WAY-100635. Mol Psychiatry. 2004;9(4):386–92.PubMedCrossRef

31.

Parsey RV, Oquendo MA, Ogden RT, Olvet DM, Simpson N, Huang YY, et al. Altered serotonin 1A binding in major depression: a [carbonyl-C-11]WAY100635 positron emission tomography study. Biol Psychiatry. 2006;59(2):106–13.PubMedCrossRef

32.

Sullivan GM, Ogden RT, Oquendo MA, Kumar JS, Simpson N, Huang YY, et al. Positron emission tomography quantification of serotonin-1A receptor binding in medication-free bipolar depression. Biol Psychiatry. 2009;66(3):223–30.PubMedCrossRef

33.

Miller JM, Brennan KG, Ogden TR, Oquendo MA, Sullivan GM, Mann JJ, et al. Elevated serotonin 1A binding in remitted major depressive disorder: evidence for a trait biological abnormality. Neuropsychopharmacology. 2009;34(10):2275–84.PubMedCrossRef

34.

Sargent PA, Rabiner EA, Bhagwagar Z, Clark L, Cowen P, Goodwin GM, et al. 5-HT(1A) receptor binding in euthymic bipolar patients using positron emission tomography with [carbonyl-(11)C]WAY-100635. J Affect Disord. 2010;123(1–3):77–80.PubMedCrossRef

35.

Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab. 2007;27(9):1533–9.PubMedCrossRef

36.

Fairchild G, Leitch MM, Ingram CD. Acute and chronic effects of corticosterone on 5-HT1A receptor-mediated autoinhibition in the rat dorsal raphe nucleus. Neuropharmacology. 2003;45(7):925–34.PubMedCrossRef

37.

Biver F, Wikler D, Lotstra F, Damhaut P, Goldman S, Mendlewicz J. Serotonin 5-HT2 receptor imaging in major depression: focal changes in orbito-insular cortex. Br J Psychiatry. 1997;171(5):444–8.PubMedCrossRef

38.

Meltzer CC, Price JC, Mathis CA, Greer PJ, Cantwell MN, Houck PR, et al. PET imaging of serotonin type 2A receptors in late-life neuropsychiatric disorders. Am J Psychiatry. 1999;156(12):1871–8.PubMed

39.

Mintun MA, Sheline YI, Moerlein SM, Vlassenko AG, Huang Y, Snyder AZ. Decreased hippocampal 5-HT2A receptor binding in major depressive disorder: in vivo measurement with [18F]altanserin positron emission tomography. Biol Psychiatry. 2004;55(3):217–24.PubMedCrossRef

40.

Sheline YI, Mintun MA, Barch DM, Wilkins C, Snyder AZ, Moerlein SM. Decreased hippocampal 5-HT(2A) receptor binding in older depressed patients using [18F]altanserin positron emission tomography. Neuropsychopharmacology. 2004;29(12):2235–41.PubMedCrossRef

41.

Attar-Levy D, Martinot JL, Blin J, Dao-Castellana MH, Crouzel C, Mazoyer B, et al. The cortical serotonin2 receptors studied with positron-emission tomography and [18F]-setoperone during depressive illness and antidepressant treatment with clomipramine. Biol Psychiatry. 1999;45(2):180–6.PubMedCrossRef

42.

Yatham LN, Liddle PF, Shiah IS, Scarrow G, Lam RW, Adam MJ, et al. Brain serotonin2 receptors in major depression: a positron emission tomography study. Arch Gen Psychiatry. 2000;57(9):850–8.PubMedCrossRef

43.

Meyer JH, Kapur S, Houle S, DaSilva J, Owczarek B, Brown GM, et al. Prefrontal cortex 5-HT2 receptors in depression: an [18F]setoperone PET imaging study. Am J Psychiatry. 1999;156(7):1029–34.PubMed

44.

Yatham LN, Liddle PF, Erez J, Kauer-Sant'Anna M, Lam RW, Imperial M, et al. Brain serotonin-2 receptors in acute mania. Br J Psychiatry. 2010;196(1):47–51.PubMedCrossRef

45.

Messa C, Colombo C, Moresco RM, Gobbo C, Galli L, Lucignani G, et al. 5-HT(2A) receptor binding is reduced in drug-naive and unchanged in SSRI-responder depressed patients compared to healthy controls: a PET study. Psychopharmacology (Berl). 2003;167(1):72–8.

46.

Bhagwagar Z, Hinz R, Taylor M, Fancy S, Cowen P, Grasby P. Increased 5-HT(2A) receptor binding in euthymic, medication-free patients recovered from depression: a positron emission study with [(11)C]MDL 100,907. Am J Psychiatry. 2006;163(9):1580–7.PubMedCrossRef

47.

Meyer JH, McMain S, Kennedy SH, Korman L, Brown GM, DaSilva JN, et al. Dysfunctional attitudes and 5-HT2 receptors during depression and self-harm. Am J Psychiatry. 2003;160(1):90–9.PubMedCrossRef

48.

Ichimiya T, Suhara T, Sudo Y, Okubo Y, Nakayama K, Nankai M, et al. Serotonin transporter binding in patients with mood disorders: a PET study with [11C](+)McN5652. Biol Psychiatry. 2002;51(9):715–22.PubMedCrossRef

49.

Reivich M, Amsterdam JD, Brunswick DJ, Shiue CY. PET brain imaging with [11C](+)McN5652 shows increased serotonin transporter availability in major depression. J Affect Disord. 2004;82(2):321–7.PubMedCrossRef

50.

Parsey RV, Hastings RS, Oquendo MA, Huang YY, Simpson N, Arcement J, et al. Lower serotonin transporter binding potential in the human brain during major depressive episodes. Am J Psychiatry. 2006;163(1):52–8.PubMedCrossRef

51.

Oquendo MA, Hastings RS, Huang YY, Simpson N, Ogden RT, Hu XZ, et al. Brain serotonin transporter binding in depressed patients with bipolar disorder using positron emission tomography. Arch Gen Psychiatry. 2007;64(2):201–8.PubMedCrossRef

52.

Miller JM, Oquendo MA, Ogden RT, Mann JJ, Parsey RV. Serotonin transporter binding as a possible predictor of one-year remission in major depressive disorder. J Psychiatr Res. 2008;42(14):1137–44.PubMedCrossRef

53.

Meyer JH, Houle S, Sagrati S, Carella A, Hussey DF, Ginovart N, et al. Brain serotonin transporter binding potential measured with carbon 11-labeled DASB positron emission tomography: effects of major depressive episodes and severity of dysfunctional attitudes. Arch Gen Psychiatry. 2004;61(12):1271–9.PubMedCrossRef

54.

Bhagwagar Z, Murthy N, Selvaraj S, Hinz R, Taylor M, Fancy S, et al. 5-HTT binding in recovered depressed patients and healthy volunteers: a positron emission tomography study with [11C]DASB. Am J Psychiatry. 2007;164(12):1858–65.PubMedCrossRef

55.

Cannon DM, Ichise M, Rollis D, Klaver JM, Gandhi SK, Charney DS, et al. Elevated serotonin transporter binding in major depressive disorder assessed using positron emission tomography and [11C]DASB; comparison with bipolar disorder. Biol Psychiatry. 2007;62(8):870–7.PubMedCrossRef

56.

Reimold M, Batra A, Knobel A, Smolka MN, Zimmer A, Mann K, et al. Anxiety is associated with reduced central serotonin transporter availability in unmedicated patients with unipolar major depression: a [11C]DASB PET study. Mol Psychiatry. 2008;13(6):606–13, 557.PubMedCrossRef

57.

Rosa-Neto P, Diksic M, Okazawa H, Leyton M, Ghadirian N, Mzengeza S, et al. Measurement of brain regional alpha-[11C]methyl-L-tryptophan trapping as a measure of serotonin synthesis in medication-free patients with major depression. Arch Gen Psychiatry. 2004;61(6):556–63.PubMedCrossRef

58.

Frey BN, Skelin I, Sakai Y, Nishikawa M, Diksic M. Gender differences in alpha-[(11)C]MTrp brain trapping, an index of serotonin synthesis, in medication-free individuals with major depressive disorder: a positron emission tomography study. Psychiatry Res. 2010;183(2):157–66.PubMedCrossRef

59.

Suhara T, Nakayama K, Inoue O, Fukuda H, Shimizu M, Mori A, et al. D1 dopamine receptor binding in mood disorders measured by positron emission tomography. Psychopharmacology (Berl). 1992;106(1):14–8.CrossRef

60.

Dougherty DD, Bonab AA, Ottowitz WE, Livni E, Alpert NM, Rauch SL, et al. Decreased striatal D1 binding as measured using PET and [11C]SCH 23,390 in patients with major depression with anger attacks. Depress Anxiety. 2006;23(3):175–7.PubMedCrossRef

61.

Cannon DM, Klaver JM, Peck SA, Rallis-Voak D, Erickson K, Drevets WC. Dopamine type-1 receptor binding in major depressive disorder assessed using positron emission tomography and [11C]NNC-112. Neuropsychopharmacology. 2009;34(5):1277–87.PubMedCrossRef

62.

Montgomery AJ, Stokes P, Kitamura Y, Grasby PM. Extrastriatal D2 and striatal D2 receptors in depressive illness: pilot PET studies using [11C]FLB 457 and [11C]raclopride. J Affect Disord. 2007;101(1–3):113–22.PubMedCrossRef

63.

Hirvonen J, Karlsson H, Kajander J, Markkula J, Rasi-Hakala H, Nagren K, et al. Striatal dopamine D2 receptors in medication-naive patients with major depressive disorder as assessed with [11C]raclopride PET. Psychopharmacology (Berl). 2008;197(4):581–90.CrossRef

64.

Meyer JH, McNeely HE, Sagrati S, Boovariwala A, Martin K, Verhoeff NP, et al. Elevated putamen D(2) receptor binding potential in major depression with motor retardation: an [11C]raclopride positron emission tomography study. Am J Psychiatry. 2006;163(9):1594–602.PubMedCrossRef

65.

Meyer JH, Kruger S, Wilson AA, Christensen BK, Goulding VS, Schaffer A, et al. Lower dopamine transporter binding potential in striatum during depression. Neuroreport. 2001;12(18):4121–5.PubMedCrossRef

66.

Remy P, Doder M, Lees A, Turjanski N, Brooks D. Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain. 2005;128(6):1314–22.PubMedCrossRef

67.

Yatham LN, Liddle PF, Lam RW, Shiah IS, Lane C, Stoessl AJ, et al. PET study of the effects of valproate on dopamine D(2) receptors in neuroleptic- and mood-stabilizer-naive patients with nonpsychotic mania. Am J Psychiatry. 2002;159(10):1718–23.PubMedCrossRef

68.

Bragulat V, Paillere-Martinot ML, Artiges E, Frouin V, Poline JB, Martinot JL. Dopaminergic function in depressed patients with affective flattening or with impulsivity: [18F]fluoro-L-dopa positron emission tomography study with voxel-based analysis. Psychiatry Res. 2007;154(2):115–24.PubMedCrossRef

69.

Cannon DM, Carson RE, Nugent AC, Eckelman WC, Kiesewetter DO, Williams J, et al. Reduced muscarinic type 2 receptor binding in subjects with bipolar disorder. Arch Gen Psychiatry. 2006;63(7):741–7.PubMedCrossRef

70.

Kano M, Fukudo S, Tashiro A, Utsumi A, Tamura D, Itoh M, et al. Decreased histamine H1 receptor binding in the brain of depressed patients. Eur J Neurosci. 2004;20(3):803–10.PubMedCrossRef

71.

Klumpers UM, Veltman DJ, Drent ML, Boellaard R, Comans EF, Meynen G, et al. Reduced parahippocampal and lateral temporal GABAA-[11C]flumazenil binding in major depression: preliminary results. Eur J Nucl Med Mol Imaging. 2010;37(3):565–74.PubMedCrossRef

72.

Meyer JH. Imaging the serotonin transporter during major depressive disorder and antidepressant treatment. J Psychiatry Neurosci. 2007;32(2):86–102.PubMed

73.

Moresco RM, Colombo C, Fazio F, Bonfanti A, Lucignani G, Messa C, et al. Effects of fluvoxamine treatment on the in vivo binding of [F-18]FESP in drug naive depressed patients: a PET study. Neuroimage. 2000;12(4):452–65.PubMedCrossRef

74.

Moses-Kolko EL, Price JC, Thase ME, Meltzer CC, Kupfer DJ, Mathis CA, et al. Measurement of 5-HT1A receptor binding in depressed adults before and after antidepressant drug treatment using positron emission tomography and [11C]WAY-100635. Synapse. 2007;61(7):523–30.PubMedCrossRef

75.

Karlsson H, Hirvonen J, Kajander J, Markkula J, Rasi-Hakala H, Salminen JK, et al. Psychotherapy increases brain serotonin 5-HT1A receptors in patients with major depressive disorder. Psychol Med. 2010;40(3):523–8.PubMedCrossRef

76.

Hirvonen J, Hietala J, Kajander J, Markkula J, Rasi-Hakala H, Salminen J, et al. Effects of antidepressant drug treatment and psychotherapy on striatal and thalamic dopamine D2/3 receptors in major depressive disorder studied with [11C]raclopride PET. J Psychopharmacol 2010; doi:10.1177/0269881110376691

77.

Kuroda Y, Motohashi N, Ito H, Ito S, Takano A, Nishikawa T, et al. Effects of repetitive transcranial magnetic stimulation on [11C]raclopride binding and cognitive function in patients with depression. J Affect Disord. 2006;95(1–3):35–42.PubMedCrossRef

78.

Yatham LN, Liddle PF, Shiah IS, Lam RW, Ngan E, Scarrow G, et al. PET study of [(18)F]6-fluoro-L-dopa uptake in neuroleptic- and mood-stabilizer-naive first-episode nonpsychotic mania: effects of treatment with divalproex sodium. Am J Psychiatry. 2002;159(5):768–74.PubMedCrossRef

79.

Yatham LN, Liddle PF, Lam RW, Adam MJ, Solomons K, Chinnapalli M, et al. A positron emission tomography study of the effects of treatment with valproate on brain 5-HT2A receptors in acute mania. Bipolar Disord. 2005;7 Suppl 5:53–7.PubMedCrossRef

80.

Kalbitzer J, Erritzoe D, Holst KK, Nielsen FA, Marner L, Lehel S, et al. Seasonal changes in brain serotonin transporter binding in short serotonin transporter linked polymorphic region-allele carriers but not in long-allele homozygotes. Biol Psychiatry. 2010;67(11):1033–9.PubMedCrossRef

Title: Molecular imaging in patients with mood disorders: a review of PET findings
Authors: Qiaozhen Chen
Weibo Liu
Huichun Li
Hong Zhang
Mei Tian
Publication date: 01-07-2011
Publisher: Springer-Verlag
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 7/2011
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-011-1779-z

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Molecular imaging in patients with mood disorders: a review of PET findings

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 7/2011

PET imaging of early response to the tyrosine kinase inhibitor ZD4190

Gastrin-releasing peptide receptor-based targeting using bombesin analogues is superior to metabolism-based targeting using choline for in vivo imaging of human prostate cancer xenografts

Focus on…: Čerenkov radiation

Parametric images via dynamic 18F-fluorodeoxyglucose positron emission tomographic data acquisition in predicting midterm outcome of liver metastases secondary to gastrointestinal stromal tumours

Early FDG PET at 10 or 20 Gy under chemoradiotherapy is prognostic for locoregional control and overall survival in patients with head and neck cancer

The prognostic value of functional tumor volume and total lesion glycolysis in patients with colorectal cancer liver metastases undergoing 90Y selective internal radiation therapy plus chemotherapy